Advances in Transfusion Safety: 2001 : Paul-Ehrlich-Institute, Langen, Germany, June 7 and 8, 2001
Fred Brown, Rainer Seitz
Karger, 2002 - Medical - 145 pages
This symposium highlighted the principle that blood transfusion is an entire process and not a single product, requiring haemovigilance and quality assurance from 'vein' to 'vein'. The prevention of contaminated blood and blood products was a major focus. Today's blood services provide remarkably safe therapeutic products that are virtually devoid of transmissible enveloped viruses. However, the risk of bacterial infection, especially in platelet concentrates, is probably underrated and may warrant routine sterility testing or universal pathogen inactivation without incurring the loss of the therapeutic functions of blood products. The unknown risk of prion transmission requires precautionary measures, including leukocyte depletion that may otherwise be beneficial in some patients. The methods for universal pathogen inactivation continue to evolve with some of them due to be licensed for use in the treatment of blood products. Stem cell transplantation portends a new chapter in haemotherapy. However, the question that no one has seriously addressed is the threshold of benefits commensurate with escalating costs that could lead to the unavailability of blood transfusion as an affordable therapy. This publication provides state-of-the-art reviews of hot topics to transfusionists, haematologists, virologists, and scientists in the plasma industry and regulatory authorities, and illustrates how the International Association for Biologicals continues to serve contemporary issues in science and society.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Safety of Donors and Recipients and Haemovigilance
Transfusion Safety 2001
a View of a Transfusionist
10 other sections not shown
Advances in Transfusion antibody apheresis associated bacterial contamination Blajchman blood and blood blood donation blood or plasma blood products blood safety blood transfusion Brown F cellular blood components CFU/mL classical CJD clinical contaminated platelets contamination of blood copies/mL Creutzfeldt-Jakob disease detection Dev Biol Evaluation follow-up genotypes haemovigilance HBsAg HBV DNA HCV NAT hepatitis human implemented inactivation incidence inoculated Karger Lancet leucodepletion leukocyte Leukocyte reduction minipool NAT reactive NAT screening NAT yield NAT-positive negative parvovirus B19 patients plasma for fractionation plasma products platelet concentrates platelet units pools prion protein recipients Red Cross reduced reported residual risk samples scrapie Seitz R eds sensitivity sepsis seroconversion serological sheep source plasma storage studies surveillance Table testing transfusion medicine transfusion reactions Transfusion Safety transmission transmitted vaccines vCJD viral load virus viruses western blot whole blood window period Yersinia enterocolitica